A recent study from the Laboratory of Molecular Signaling, University of California Los Angeles, Los Angeles, California, USA shows that “Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB.”
This study was published in the 10 August, 2014 issue of Nature Medicine (The number 1 journal in Medicine with an IF of ~35) by Prof. Wang, Bo and others from the Laboratory of Molecular Signaling, University of California Los Angeles, Los Angeles, California, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based therapy for Osteoporosis and its related disorders: Progestin inhibits osteoporosis and skeletal ageing by inhibiting the Wnt4 pathway. This study suggests, for the first time, that Progestin, by down regulating its target genes, it may increase the expression of Wnt4 and its downstream components. Thereby, it may (1) decelerate bone loss in osteoporosis; (2) strengthen bones; (3) and inhibit skeletal ageing. Together, this study suggests that pharmacological formulations encompassing “Progestin activators or small molecule compounds that increase the expression of Progestin” may be used to treat osteoporosis and ageing-associated skeletal disorders.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan,L., MiRNA-based therapy for Osteoporosis and its related disorders: Progestin inhibits osteoporosis and skeletal ageing by inhibiting the Wnt4 pathway, Genome-2-Bio-Medicine Discovery center (GBMD), 8/October/2014, 10.23 am, http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
